Overview GAIA’s digital therapeutic deprexis is now reimbursable in Switzerland for patients with mild to moderate depression and recurrent depressive disorders under the country’s man...
Overview A secondary analysis of a randomized controlled trial published in Behaviour Research and Therapy found that somnovia, GAIA’s digital insomnia therapy, primarily imp...
Overview GAIA reported positive results from a randomized controlled trial published in Psychological Medicine, demonstrating that attexis significantly reduced ADH...
GAIA and Daiichi Sankyo Europe Partner to Commercialize Digital Therapeutic for Hypercholesterolemia
Overview GAIA and Daiichi Sankyo Europe have entered an exclusive strategic partnership to commercialize lipodia, a digital therapeutic designed to support adults living with hyperchol...
